Immune Thrombocytopenic Purpura

Immune Thrombocytopenic Purpura (ITP) is an acquired autoimmune disorder characterized by an isolated decrease in the circulating platelet count (thrombocytopenia) to less than 100,000/µL in the absence of other causes. The condition results from both the premature destruction of platelets by the reticuloendothelial system and the impaired production of platelets in the bone marrow. Clinically, it manifests as a spectrum ranging from asymptomatic presentation to life-threatening mucosal or intracranial hemorrhage. It is categorized as "primary" when it occurs in isolation and "secondary" when associated with underlying conditions like infections or other autoimmune diseases.

The exact cause of primary ITP remains unknown (idiopathic), though it is widely accepted to be an immune-mediated loss of self-tolerance. Secondary ITP can be triggered by:

• Viral Infections: HIV, Hepatitis C (HCV), Cytomegalovirus (CMV), and Varicella-zoster.

• Autoimmune Diseases: Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome.


• Malignancies: Chronic Lymphocytic Leukemia (CLL) and lymphomas.


• Vaccinations: Rarely associated with the MMR vaccine in children.

The pathophysiology of ITP is multifactorial, involving both humoral and cellular immunity:

1. Platelet Destruction: B-cells produce autoantibodies (mostly IgG) directed against platelet surface glycoproteins, such as GPIIb/IIIa or GPIb/IX. These antibody-coated platelets are recognized by Fc receptors on splenic macrophages, leading to their phagocytosis and destruction.


2. Impaired Production: Autoantibodies also target megakaryocytes (platelet precursors) in the bone marrow, leading to reduced platelet shedding. Additionally, levels of thrombopoietin (TPO) are often inappropriately low for the degree of thrombocytopenia.


3. T-cell Involvement: Cytotoxic T-cells may directly lyse platelets or interfere with megakaryocyte maturation.

• Incidence: Approximately 3.3 per 100,000 adults per year.
• Age Distribution: Bimodal distribution. In children, it often presents as an acute post-viral condition. In adults, it is typically chronic, peaking in the 30–50 age range and again in those over

• Gender: In young adults, females are affected more frequently than males (2:1 ratio). In children and the elderly, the gender distribution is roughly equal.

• Pre-existing autoimmune disorders (e.g., SLE, thyroid disease).
• Recent viral illness (especially in pediatric populations).
• Chronic infections (HIV, Hepatitis C).
• Family history of autoimmune cytopenias.

A. Early Symptoms

• Easy bruising without clear trauma.


• Appearance of tiny red dots on the skin (petechiae). B. Common Symptoms


• Purpura (larger purple/blue bruises).


• Epistaxis (nosebleeds) that are difficult to stop.


• Gingival bleeding (bleeding gums).


• Menorrhagia (abnormally heavy menstrual cycles). C. Advanced Symptoms


• Gastrointestinal bleeding (melena or hematochezia).


• Hematuria (blood in urine).


• Large hematomas. D. Emergency Symptoms


• Sudden, severe headache or neurological deficits (indicative of intracranial hemorrhage).


• Significant, uncontrolled mucosal bleeding ("wet purpura").


• Hemoptysis (coughing up blood).

• Vital Signs: Generally normal unless severe hemorrhage has occurred (tachycardia, hypotension).
• Inspection: Petechiae (non-blanching, usually on dependent limbs), purpura, and ecchymoses.
• HEENT: Oropharyngeal petechiae or hemorrhagic bullae (wet purpura).

A. Clinical Assessment: History of bleeding symptoms, medication review, and exclusion of other causes.
B. Laboratory Testing: Complete Blood Count (CBC) and peripheral blood smear are essential.
C. Imaging Studies: Generally not required unless checking for splenomegaly or intracranial bleeding.
D. Functional Tests: Rarely used in clinical practice.
E. Biopsy Findings: Bone marrow aspiration/biopsy is indicated in patients >60 years or those with atypical features.
F. Genetic Testing: Not standard, but may be used to rule out inherited thrombocytopenias (e.g., MYH9-related disease).
G. Differential Diagnosis: Crucial to rule out TTP, HUS, and HIT.

Complete Blood Count (CBC)
Type: Blood Test
Purpose: To quantify platelet count and evaluate other cell lines.
Expected Findings: Isolated thrombocytopenia (<100,000/µL).
Interpretation: Normal hemoglobin and WBC counts suggest primary ITP; abnormalities in other lines suggest secondary causes. Peripheral Blood Smear
Type: Blood Test
Purpose: To rule out pseudothrombocytopenia and morphology-based disorders.
Expected Findings: Reduced platelet numbers; presence of large "stress" platelets (megathrombocytes).
Interpretation: Absence of schistocytes rules out TTP/HUS; absence of blasts rules out leukemia. HIV and Hepatitis C Serology
Type: Blood Test
Purpose: To identify secondary causes of ITP.
Expected Findings: Positive or negative for viral antibodies.
Interpretation: Positive results indicate secondary ITP requiring specific antiviral management.

• Abdominal Ultrasound/CT: Purpose is to assess spleen size. Typical Findings: Normal-sized spleen. Clinical Importance: Enlarged spleen suggests portal hypertension or lymphoma rather than primary ITP.
• Head CT/MRI: Purpose is to evaluate for intracranial hemorrhage. Typical Findings: Intracranial blood in acute cases. Clinical Importance: Essential for emergency management of neurologic symptoms.

• Thrombotic Thrombocytopenic Purpura (TTP): Distinguished by schistocytes on smear, fever, and neurological/renal symptoms.
• Heparin-Induced Thrombocytopenia (HIT): Distinguished by recent heparin exposure and thrombotic risk.
• Myelodysplastic Syndrome (MDS): Distinguished by cytopenias in multiple cell lines and dysplastic cells in marrow.
• Gestational Thrombocytopenia: Occurs only during pregnancy, usually mild (>70,000/µL).

• Severe hemorrhage (intracranial, gastrointestinal).
• Side effects of long-term steroid use (osteoporosis, diabetes, weight gain).
• Post-splenectomy sepsis (overwhelming post-splenectomy infection).
• Iron deficiency anemia from chronic blood loss.

A. Lifestyle Modifications: Avoid contact sports and NSAIDs/aspirin which inhibit platelet function.
B. Preventive Measures: Vaccination for splenectomy candidates (Pneumococcal, Meningococcal, H. influenzae).
C. Medical Treatment
| Drug Class | Mechanism | Examples |
| :--- | :--- | :--- |
| Corticosteroids | Immune suppression, reduced clearance | Prednisone, Dexamethasone |
| Intravenous Immunoglobulin (IVIG) | Rapidly saturates Fc receptors on macrophages | Privigen, Gammagard |
| Anti-D Immunoglobulin | "Distracts" macrophages (only for Rh+ patients) | WinRho |
| TPO-Receptor Agonists | Stimulates platelet production in bone marrow | Romiplostim, Eltrombopag |
| Monoclonal Antibodies | B-cell depletion (anti-CD20) | Rituximab | D. Surgical Treatment: Splenectomy (the primary site of platelet destruction and autoantibody production).
E. Interventional Procedures: None standard.
F. Rehabilitation: Not typically required.
G. Emergency Management: High-dose steroids, IVIG, and platelet transfusions for life-threatening bleeding.

• Children: Excellent; ~80% experience spontaneous remission within 6 months.
• Adults: Frequently becomes chronic. Remission rates with first-line therapy are ~50-70%, but many require second-line agents.
• Mortality: Rare (<1%), usually due to intracranial hemorrhage.

• Primary: None, as the trigger is often unknown.
• Secondary: Screening for H. pylori, HIV, and HCV in newly diagnosed cases to allow for targeted treatment of the underlying cause.

The following homeopathic remedies have been historically indicated for symptoms associated with Immune Thrombocytopenic Purpura. Selection should be based on individualized symptom totality and constitutional assessment.

• Homeopathy by Hadhrat Mirza Tahir Ahmad (r.a.) — Primary clinical reference
• Robin Murphy — Lotus Materia Medica (3rd Edition)
• William Boericke — Pocket Manual of Homœopathic Materia Medica & Repertory
• ICD-10/ICD-11 Classification — World Health Organization
• Harrison's Principles of Internal Medicine (Reference Standard)

This clinical reference profile is compiled from authoritative medical sources for educational purposes. Always verify clinical data with current medical guidelines.

📊 Immune System Resilience Score

Calculates a general immune system resilience score based on lifestyle factors (sleep, stress, exercise, nutrition) and historical infection rates.